A practical cost analysis of Bivalirudin

Pharmacotherapy

Volumn 22, Issue 6 II, 2002, Pages

  Compton, Anthony ^a  

^a Saint Joseph's Hospital of Atlanta   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIRULOG; ANTICOAGULANT AGENT; DRUG DERIVATIVE; FIBRINOLYTIC AGENT; HEPARIN; HIRUDIN DERIVATIVE; PEPTIDE FRAGMENT; RECOMBINANT PROTEIN;

ANGIOPLASTY; BLEEDING; COST BENEFIT ANALYSIS; HEALTH CARE COST; HEART CATHETERIZATION; HEART MUSCLE ISCHEMIA; HOSPITAL COST; HUMAN; MATHEMATICAL MODEL; MEDICAL FEE; REVIEW; STATISTICAL ANALYSIS; TRANSLUMINAL CORONARY ANGIOPLASTY; AGED; ARTICLE; BLOOD TRANSFUSION; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; COST; ECONOMICS; FEMALE; HEART INFARCTION; KIDNEY FAILURE; METABOLISM; RANDOMIZED CONTROLLED TRIAL; REOPERATION;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; BLOOD TRANSFUSION; COSTS AND COST ANALYSIS; FEMALE; FIBRINOLYTIC AGENTS; HEPARIN; HIRUDINS; HUMANS; KIDNEY FAILURE; MYOCARDIAL INFARCTION; PEPTIDE FRAGMENTS; RANDOMIZED CONTROLLED TRIALS; RECOMBINANT PROTEINS; REOPERATION;

EID: 0036259863     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.22.10.119s.33615     Document Type: Review

References (25)

1. Mathematical modeling in the assessment of quality improvement and cost reduction efforts in percutaneous coronary interventions
2. The impact of statistical adjustment on economic profiles of interventional cardiologists
3. In-hospital cost of percutaneous coronary revascularization: Critical determinants and implications
4. Reducing costs and improving outcomes of percutaneous transluminal coronary interventions
5. Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty
6. Practice patterns and outcomes of percutaneous coronary intervention in the United States: 1995 to 1997
7. Outcomes and cost of ischemic complications and bleeding in patients undergoing percutaneous coronary interventions
8. Economic impact of GP IIb/IIIa blockade after high-risk angioplasty: Results from the RESTORE trial. Randomized efficacy study of tirofiban for outcomes and restenosis
9. Clinical correlates of the initial and long-term cost of coronary bypass surgery and coronary angioplasty
10. Evaluating the potential cost-effectiveness of stenting as a treatment for symptomatic single-vessel coronary disease: Use of a decision-analytic model
11. Economics of elective coronary revascularization: Comparison of costs and charges for conventional angioplasty, directional atherectomy, stenting and bypass surgery
12. Clinical correlates of in-hospital costs for acute myocardial infarction in patients 65 years of age and older
13. Antithrombin, antiplatelet therapy or both during PCI: A preliminary randomized trial
14. Bivalirudin versus heparin during coronary angioplasty for unstable or post-infarction angina: Final reanalysis of the bivalirudin angioplasty study
15. Direct thrombin inhibitors in acute coronary syndromes: Principal results of a meta-analysis based on individual patients' data
16. Pilot study of bivalirudin versus heparin during percutaneous coronary intervention with stenting and GP IIb/IIIa blockade: Results of the REPLACE 1 Trial [abstr]
17. Frequency, predictors, and appropriateness of blood transfusion after percutaneous coronary interventions
18. A controlled trial of educational outreach to improve blood transfusion practice
19. Subcutaneous heparin in postangioplasty management: Comparative trial with intravenous heparin
20. Heparin after percutaneous intervention (HAPI): A prospective multicenter randomized trial of three heparin regimens after successful coronary intervention
21. Cost analysis of bivalirudin in percutaneous coronary intervention
22. Variability in cost of coronary bypass surgery in New York State: Potential for cost savings